Research ExplorerPublicationsSmoking does not Alter the Therapy Response to Systemic Anti...

Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies - A Two-country, Multi-centre, Prospective, Non-interventional Study

Standard

Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies - A Two-country, Multi-centre, Prospective, Non-interventional Study. / Anzengruber, Florian; Augustin, Matthias; Radtke, Marc A; Thaci, Diamant; Yawalkar, Nikhil; Streit, Markus; Reich, Kristian; Drach, Mathias; Sorbe, Christina; French, Lars E; Mrowietz, Ulrich; Maul, Julia-Tatjana; Itin, Peter H; Navarini, Alexander A.

In: ACTA DERM-VENEREOL, Vol. 99, No. 10, 01.09.2019, p. 871-877.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Anzengruber, F, Augustin, M, Radtke, MA, Thaci, D, Yawalkar, N, Streit, M, Reich, K, Drach, M, Sorbe, C, French, LE, Mrowietz, U, Maul, J-T, Itin, PH & Navarini, AA 2019, 'Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies - A Two-country, Multi-centre, Prospective, Non-interventional Study', ACTA DERM-VENEREOL, vol. 99, no. 10, pp. 871-877. https://doi.org/10.2340/00015555-3221

APA

Anzengruber, F., Augustin, M., Radtke, M. A., Thaci, D., Yawalkar, N., Streit, M., Reich, K., Drach, M., Sorbe, C., French, L. E., Mrowietz, U., Maul, J-T., Itin, P. H., & Navarini, A. A. (2019). Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies - A Two-country, Multi-centre, Prospective, Non-interventional Study. ACTA DERM-VENEREOL, 99(10), 871-877. https://doi.org/10.2340/00015555-3221

Vancouver

Anzengruber F, Augustin M, Radtke MA, Thaci D, Yawalkar N, Streit M et al. Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies - A Two-country, Multi-centre, Prospective, Non-interventional Study. ACTA DERM-VENEREOL. 2019 Sep 1;99(10):871-877. https://doi.org/10.2340/00015555-3221

Bibtex

@article{a399f594aea5493b8ffcee46949b99ed,
title = "Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies - A Two-country, Multi-centre, Prospective, Non-interventional Study",
abstract = "Psoriasis can involve the skin, joints, nails and cardiovascular system and result in a significant impairment in quality of life. Studies have shown a lower response rate to systemic anti-psoriatic therapies in smokers, and smoking is a trigger factor for psoriasis. The aim of this study was therefore to analyse the response to systemic therapies for psoriasis, with a focus on smoking. Prospectively collected data from patients with moderate to severe psoriasis included in the national psoriasis registries for Germany and Switzerland (PsoBest and SDNTT) were analysed. Therapy response was defined as reaching a Psoriasis Area and Severity Index (PASI) reduction of 75%, PASI ≤ 3 or Dermatology Life Quality Index (DLQI) ≤ 1. Out of 5,346 patients included in these registries, 1,264 met the inclusion criteria for this study. In the smoking group, 715 (60.6%) reached therapy response at month 3, compared with 358 (63.7%) in the non-smoking group (p ≤ 0.269), 659 (74.1%) vs. 330 (77%) reached therapy response at month 6 (p ≤ 0.097), and 504 (76.6%) vs. 272 (79.0%) at month 12 (p ≤ 0.611). Therefore, these data do not show that smoking affects the response rate of anti-psoriatic therapy after 3, 6 and 12 months.",
author = "Florian Anzengruber and Matthias Augustin and Radtke, {Marc A} and Diamant Thaci and Nikhil Yawalkar and Markus Streit and Kristian Reich and Mathias Drach and Christina Sorbe and French, {Lars E} and Ulrich Mrowietz and Julia-Tatjana Maul and Itin, {Peter H} and Navarini, {Alexander A}",
year = "2019",
month = sep,
day = "1",
doi = "10.2340/00015555-3221",
language = "English",
volume = "99",
pages = "871--877",
journal = "ACTA DERM-VENEREOL",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "10",

}

RIS

TY - JOUR

T1 - Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies - A Two-country, Multi-centre, Prospective, Non-interventional Study

AU - Anzengruber, Florian

AU - Augustin, Matthias

AU - Radtke, Marc A

AU - Thaci, Diamant

AU - Yawalkar, Nikhil

AU - Streit, Markus

AU - Reich, Kristian

AU - Drach, Mathias

AU - Sorbe, Christina

AU - French, Lars E

AU - Mrowietz, Ulrich

AU - Maul, Julia-Tatjana

AU - Itin, Peter H

AU - Navarini, Alexander A

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Psoriasis can involve the skin, joints, nails and cardiovascular system and result in a significant impairment in quality of life. Studies have shown a lower response rate to systemic anti-psoriatic therapies in smokers, and smoking is a trigger factor for psoriasis. The aim of this study was therefore to analyse the response to systemic therapies for psoriasis, with a focus on smoking. Prospectively collected data from patients with moderate to severe psoriasis included in the national psoriasis registries for Germany and Switzerland (PsoBest and SDNTT) were analysed. Therapy response was defined as reaching a Psoriasis Area and Severity Index (PASI) reduction of 75%, PASI ≤ 3 or Dermatology Life Quality Index (DLQI) ≤ 1. Out of 5,346 patients included in these registries, 1,264 met the inclusion criteria for this study. In the smoking group, 715 (60.6%) reached therapy response at month 3, compared with 358 (63.7%) in the non-smoking group (p ≤ 0.269), 659 (74.1%) vs. 330 (77%) reached therapy response at month 6 (p ≤ 0.097), and 504 (76.6%) vs. 272 (79.0%) at month 12 (p ≤ 0.611). Therefore, these data do not show that smoking affects the response rate of anti-psoriatic therapy after 3, 6 and 12 months.

AB - Psoriasis can involve the skin, joints, nails and cardiovascular system and result in a significant impairment in quality of life. Studies have shown a lower response rate to systemic anti-psoriatic therapies in smokers, and smoking is a trigger factor for psoriasis. The aim of this study was therefore to analyse the response to systemic therapies for psoriasis, with a focus on smoking. Prospectively collected data from patients with moderate to severe psoriasis included in the national psoriasis registries for Germany and Switzerland (PsoBest and SDNTT) were analysed. Therapy response was defined as reaching a Psoriasis Area and Severity Index (PASI) reduction of 75%, PASI ≤ 3 or Dermatology Life Quality Index (DLQI) ≤ 1. Out of 5,346 patients included in these registries, 1,264 met the inclusion criteria for this study. In the smoking group, 715 (60.6%) reached therapy response at month 3, compared with 358 (63.7%) in the non-smoking group (p ≤ 0.269), 659 (74.1%) vs. 330 (77%) reached therapy response at month 6 (p ≤ 0.097), and 504 (76.6%) vs. 272 (79.0%) at month 12 (p ≤ 0.611). Therefore, these data do not show that smoking affects the response rate of anti-psoriatic therapy after 3, 6 and 12 months.

U2 - 10.2340/00015555-3221

DO - 10.2340/00015555-3221

M3 - SCORING: Journal article

C2 - 31099404

VL - 99

SP - 871

EP - 877

JO - ACTA DERM-VENEREOL

JF - ACTA DERM-VENEREOL

SN - 0001-5555

IS - 10

ER -